Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a special purpose acquisition company whose warrants trade on the public markets under the ticker TDACW. The company's name reflects a focus on the life sciences and translational medicine space, targeting businesses that move early-stage scientific research into clinical or commercial applications. On May 15, 2026, the company filed a Form 10-Q quarterly report with the SEC, under accession number 0001104659-26-061556, consistent with its ongoing reporting obligations as an active SPAC. Investors tracking TDACW can access sponsor details, IPO vintage, deal-stage timelines, and comparable transaction data by signing up for a full account on SpacDesk.